Immune Thrombocytopenia (ITP) Market Research Report - Forecast till 2027

Immune Thrombocytopenia (ITP) Market: By Treatment (Intravenous immunoglobulins, Corticosteroids, Thrombopoietin receptor agonists, Others), By End-user (Hospitals and clinics, Specialty Centers, Research and Academic Institutes, others) — Forecast till 2027

ID: MRFR/Pharma/5531-CR | December 2018 | Region: Global | 105 Pages         

Immune Thrombocytopenia (ITP) Market Speak to Analyst Request a Free Sample

Immune Thrombocytopenia (ITP) Market

Immune Thrombocytopenia (ITP) Market will grow at CAGR of 1.2% to hit $ 3.5 Billion by 2030

By Treatment Intravenous immunoglobulins Corticosteroids Thrombopoietin receptor agonists
By End-user Hospitals and clinics Specialty Centers Research and Academic Institutes
Key Players
Companies Profiled   CSL Limited    Amgen Inc.   F.Hoffmann-La Roche Ltd.   Kyowa Hakko Kirin Co.Ltd.   Rigel Pharmaceuticals Inc.   Shionogi Inc.   Dova Pharmaceuticals   Novartis AG   Jiangsu Hengrui Pharmaceutical Co.Ltd.   Shire and Ligand Pharmaceuticals Inc.
Market Driving Forces   increased focus on development of novel drugs and therapeutics is also having a positive impact on the market
Request a Free Sample

Immune Thrombocytopenia (ITP) Market Overview The Immune Thrombocytopenia market is projected to surpass a valuation of USD 2,300 Mn at 5.78% CAGR during the forecast period. Idiopathic thrombocytopenia (ITP), also known as immunological thrombocytopenic purpura or idiopathic thrombocytopenic purpura, is an autoimmune condition in which the body assaults and kills platelets too quickly. ITP is a blood platelet condition that affects the total amount of platelets rather than their function. A low platelet count causes excessive bleeding, which causes many of the symptoms of ITP. Frequent bleeding episodes can lead to anemia (low amounts of circulating red blood cells), which can induce fatigue and impede reaction to exertion in severe cases. Serious bleeding into the brain (intracranial hemorrhage) can happen in rare situations. Immune Thrombocytopenia (ITP) treatments are in high demand due to the rising prevalence of immunological thrombocytopenia (ITP) around the world. The global ITP market has benefited from increased government efforts to develop healthcare infrastructure in countries such as India, China, and Brazil. Furthermore, increased focus on the development of innovative medications and therapies is benefiting the industry. Secondary triggers of ITP include autoimmune illnesses, persistent infections, medicines, pregnancy, and some malignancies. There are two basic kinds of ITP i.e. Acute (short-term) and chronic (long-term). Based on the cause of the disease, ITP is classified as main or secondary. Primary ITP refers to immune-mediated thrombocytopenia without other causes or disorders that may be associated with thrombocytopenia, whereas secondary ITP refers to immune-mediated thrombocytopenia with an underlying cause, such as drug-induced or associated with systemic illness.

Immune Thrombocytopenia Market Synopsis:

The MRFR report includes a thorough assessment of the global immune thrombocytopenia (ITP) market along with a five-year (2018-2023) revenue forecast. The report includes a discussion on several key market elements. The scope of the discussion also covers different ITP treatments that are currently available such as intravenous immunoglobulins, thrombopoietin receptor agonists and corticosteroids among other. It also covers revenue analysis of major end-users of immune thrombocytopenia, which covers hospitals and clinics, specialty centers, and research and academic institutes.  A detail analysis of the various sub-markets across key region of the world is also available in the report.

Report Coverage:

Historical market trends, market dynamics, forecast, market value by region as well as by segmentation, country-level analysis for each market segment, key player’s market share analysis and market factor analysis which covers supply chain and Porter’s five forces analysis of the market

Immune Thrombocytopenia Market Key Players:

CSL Limited, Amgen Inc., F.Hoffmann-La Roche Ltd., Kyowa Hakko Kirin Co., Ltd., Rigel Pharmaceuticals, Inc., Shionogi Inc., Dova Pharmaceuticals, Novartis AG, Jiangsu Hengrui Pharmaceutical Co., Ltd., Shire and Ligand Pharmaceuticals, Inc.

For the scope of the research, MRFR’s report offers a comprehensive segmental analysis of the Immune Thrombocytopenia market

By Treatment:

  • Intravenous immunoglobulins

  • Corticosteroids

  • Thrombopoietin receptor agonists

  • Others

By End-user:

  • Hospitals and clinics

  • Specialty centers

  • Research and academic institutes

  • Others

By Region:

  • Americas

  • Europe

  • Asia Pacific (APAC)

  • The Middle East & Africa (MEA)

Research Methodology:

The research methodology envelops the range and depth of Immune Thrombocytopenia market and industries that ensures the best outlooks are presented. The methodology successfully combines primary and secondary research methods to present exclusive and pertinent content that can aid in well-versed decision making. The different advances in markets are uniquely included in the reports by employing top-down and bottom-up approaches. Insightful data, advantageous scenarios, and outline of the emerging markets make for a complete and astute guide into the beat of the market. Also, the consistency levels of our reports offer our users adept intelligence that can shape the base of strategies they devise to gain the preferred market portions and hold & enhance their current customer base in several geographies.   Recent Development

Biotest became the first plasma protein company in Germany to create an experimental hyper immunoglobulin preparation against COVID-19 in February 2021. The market for Immune Thrombocytopenia (ITP) treatments is moderately competitive, with several significant companies. Grifols SA agreed to purchase GC Pharma Group's plasma fractionation and purification facilities in Montreal, as well as 11 plasma collection centers in the United States, in July 2020.

Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

Immune thrombocytopenia (ITP) market is projected to grow at a 5.78% CAGR during the forecast period.

Immune thrombocytopenia (ITP) market is predicted to touch USD 2,300 million during the forecast period.

The Americas is expected to lead the immune thrombocytopenia (ITP) market.

Rising prevalence of ITP and focus on developing new drugs are the key factors driving the immune thrombocytopenia (ITP) market.

Risk of side effects may limit the immune thrombocytopenia (ITP) market.